Last --
Change Today 0.00 / 0.00%
Volume 0.0
4589 On Other Exchanges
Symbol
Exchange
4589 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

acucela inc (4589) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACUCELA INC (4589)

Related News

No related news articles were found.

acucela inc (4589) Related Businessweek News

No Related Businessweek News Found

acucela inc (4589) Details

Acucela Inc. discovers and develops therapeutic products to treat and slow the progression of sight-threatening ophthalmic diseases worldwide. It focuses on developing oral products based on its proprietary visual cycle modulation (VCM) compounds to address various retinal diseases, primarily age-related macular degeneration, diabetic retinopathy, and diabetic macular edema, as well as potentially Stargardt disease, retinitis pigmentosa, and retinopathy of prematurity. The company’s product candidates include Emixustat hydrochloride, which is in Phase IIb/III clinical trial for the treatment of age-related macular degeneration; and OPA-6566, an adenosine A2a receptor agonist that is in Phase I/II clinical trial to treat ocular hypertension and open-angle glaucoma as a topical ophthalmic solution. It has a co-development and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. for Emixustat and OPA-6566. Acucela Inc. was founded in 2002 and is based in Seattle, Washington.

84 Employees
Last Reported Date: 03/28/14
Founded in 2002

acucela inc (4589) Top Compensated Officers

Founder, Chairman and Chief Executive Officer
Total Annual Compensation: $521.9K
Vice President of Human Resources
Total Annual Compensation: $259.5K
Compensation as of Fiscal Year 2013.

acucela inc (4589) Key Developments

Acucela Inc. Announces Board Appointments

Acucela Inc. announced that Brian O’Callaghan, the company’s President and Chief Operating Officer, will assume the role of Chief Executive Officer, along with continuing to serve as Interim Chief Financial Officer. Ryo Kubota, M.D., Ph.D., the company’s Founder, will retain his position as Chairman of the company’s Board of Directors. Mr. O’Callaghan will assume the role of CEO effective January 1, 2015.

Acucela Inc. Revises Earnings Guidance for the Year Ending December 31, 2014

Acucela Inc. revised earnings guidance for the year ending December 31, 2014. For the year, the company now expects revenue from collaborations to be $34,739,000 against previously expected of $61,840,000. Operating income to be $693,000 against previously expected of $836,000. Income before income tax to be $250,000 against previously expected of $433,000. Net loss to be $1,997,000 or $0.06 per share against previously expected net income of $264,000 or $0.02 per share.

Acucela Inc. Announces Results on the Pharmacodynamic Properties of Emixustat Hydrochloride in Patients

Acucela Inc. announced that results on the pharmacodynamic properties of emixustat hydrochloride in patients with geographic atrophy will be presented by Roger L. Novack, MD, PhD, Retina-Vitreous Associates Medical Group, Beverly Hills, California, during a podium session at the American Academy of Ophthalmology (AAO) 2014 Annual Meeting in Chicago, IL on October 21, 2014 at 10:46AM, CT. Emixustat, the first internally developed investigational compound by Acucela, is orally dosed, targets the visual cycle, and is in development for the treatment of GA associated with dry AMD. Dr. Novack was one of the investigators in Acucela's Phase 2a clinical study and is currently participating as an investigator in the Phase 2b/3 "SEATTLE" study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4589:JP ¥603.00 JPY -29.00

4589 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4589.
View Industry Companies
 

Industry Analysis

4589

Industry Average

Valuation 4589 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.6x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACUCELA INC, please visit www.acucela.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.